Division of Genome Medicine 

Dr. Toyomasa Katagiri's Laboratory

LinkIconEnglish

HOME | 業績

更新日 2017-11-04 | 作成日 2017-11-04

原著論文(2008年以降)

業 績

(*Corresponding author)(○:当研究室が主となって行った研究成果)

2019

  1. ○*Low SK, Ito H, Matsuo K, Tanikawa C, Matsuda K, Saito H, Sakurai-Yageta M, Nakaya N, Shimizu A, Nishizuka SS, Yamaji T, Sawada N, Iwasaki M, Tsugane S, Takezaki T, Suzuki S, Naito M, Waka K, Kamatani Y, Momozawa Y, Murakami Y, Inazawa J, Nakamura Y, Kubo M, Katagiri T, * Miki Y. Identification of the two novel breast cancer loci through large-scale genome-wide association study in the Japanese population. Sci Rep. In press.
  2. Fujimoto Y, Inoue, N, Morimoto K, Watanabe T, Hirota S, Imamura M, Matsushita Y, Katagiri T, Okamura H, *Miyoshi Y. Significant association between high serum CCL5 levels and better disease-free survival of patients with early breast cancer. Cancer Sci. 2019 in press. (IF:4.751)
  3. ○ #Kimura R, #Yoshimaru T, #Matsushita Y, Matsuo T, Ono M, Park JH, Sasa M, Miyoshi Y, Nakamura Y, *Katagiri T. The GALNT6-LGALS3BP axis promotes breast cancer cell growth. Int J Oncol. in press (IF:3.571), (# equal contribution)
  4. Ohigashi I, Tanaka Y, Kondo K, Fujimori S, Kondo H, Palin AC, Kozai M, Matsushita Y, Uda S, Kubota H, Murata S, Tanaka K, Katagiri T, Kosako H, *Takahama Y. Trans-omics impact of thymoproteasome in cortical thymic epithelial cells. Cell Rep. in press. (IF:7.815)
  5. Inoue N, Li W, Fujimoto Y, Matsushita Y, Katagiri T, Okamura H, *Miyoshi Y. High Serum Levels of Interleukin-18 Are Associated With Worse Outcomes in Patients With Breast Cancer. Anticancer Res. 2019 Sep;39(9):5009-5018. (IF: 1.935)
  6. Chigira T, Nagatoishi S, Takeda H, Yoshimaru T, Katagiri T, *Tsumoto K. Biophysical characterization of the breast cancer-related BIG3-PHB2 interaction: Effect of non-conserved loop region of BIG3 on the structure and the interaction. Biochem Biophys Res Commun. 2019 Oct 8;518(1):183-189. (IF: 2.705)


2018

  1. *Momozawa Y, Iwasaki Y, Parsons MT, Kamatani Y, Takahashi A, Tamura C, Katagiri T, Yoshida T, Nakamura S, Sugano K, Miki Y, Hirata M, Matsuda K, Spurdle AB, *Kubo M. Germline pathogenic variants of 11 breast cancer genes in 7,051 Japanese patients and 11,241 controls. Nat Commun. 2018 Oct 4;9(1):4083.
  2. Deng B, Tarhan YE, Ueda K, Ren L, Katagiri T, Park JH, *Nakamura Y. Critical role of estrogen receptor alpha O-glycosylation by N-acetylgalactosaminyltransferase 6 (GALNT6) in its nuclear localization in breast cancer cells. Neoplasia. 2018 Oct;20(10):1038-1044.
  3. Giraudet AL, Cassier PA, Iwao-Fukukawa C, Garin G, Badel JN, Kryza D, Chabaud S, Gilles-Afchain L, Clapisson G, Desuzinges C, Sarrut D, Halty A, Italiano A, Mori M, Tsunoda T, Katagiri T, Nakamura Y, Alberti L, Cropet C, Baconnier S, Berge-Montamat S, Pérol D, Blay JY. A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients. BMC Cancer. 2018 Jun 8;18(1):646.
  4. Kato Y, Zembutsu H, Takata R, Matsuura T, Kato R, Kanehira M, Iwasaki K, Yamada N, Katagiri T, Sugai T, Fujioka T, Nakamura Y, *Obara W. A prospective study to examine the accuracies and efficacies of prediction systems for response to neoadjuvant chemotherapy for muscle invasive bladder. Oncology Letters. 2018, Nov;16(5):5775-5784.
  5. Li HK, Sugyo A, Tsuji AB, Morokoshi Y, Minegishi K, Nagasu K, Kanda H, Harada Y, Nagayama S, Katagiri T, Nakamura Y, Higashi T, Hasegawa S. alpha-particle therapy for synovial sarcoma in the mouse using an astatine-211-labeled antibpdy against fizzled homolog 10. Cancer Sci. 2018 Jul;109(7):2302-2309.
  6. 〇 Daizumoto K, Yoshimaru T, Matsushita Y, Fukawa T, Uehara H, Ono M, Komatsu M, Kanayama H, *Katagiri T. A DDX31/mutant-p53/EGFR axis promotes multistep progression of muscle invasive bladder cancer. Cancer Res., 2018 May 1;78(9):2233-2247.
  7. ○ Miyagawa Y#, Matsushita Y#, Suzuki H, Komatsu M, Yoshimaru T, Kimura R, Yanai A, Honda J, Tangoku A, Sasa M, Miyoshi Y, *Katagiri T. Frequent downregulation of LRRC26 by epigenetic alterations is involved in the malignant progression of triple-negative breast cancers. Int J Oncol. 2018 Mar 5. (# contributed equally)
  8. Sato S, Nakamura T, Katagiri T, Tsuchikawa T, Kushibiki T, Hontani K, Takahashi M, Inoko K, Takano H, Abe H, Takeuchi S, Ono M, Kuwabara S, Umemoto K, Suzuki T, Sato O, Nakamura Y, Hirano S. Molecular targeting of cell-permeable peptide inhibits pancreatic ductal adenocarcinoma cell proliferation. Oncotarget. 2017 Oct 19;8(69):113662-113672.
  9. Obara W, Kanehira M, Katagiri T, Kato R, Kato Y, Takata R. Present status and future perspective of peptide-based vaccine therapy for urological cancer. Cancer Sci. 2018, Mar; 109(3):550-559.


2017

  1. Nishimukai A, Inoue N, Kira A, Takeda M, Morimoto K, Araki K, Kitajima K, Watanabe T, Hirota S, Katagiri T, Nakamori S, Akazawa K, Miyoshi Y*. Tumor size and proliferative marker geminin rather than Ki67 expression levels significantly associated with maximum uptake of 18F-deoxyglucose levels on positron emission tomography for breast cancers. PLoS One. 2017 Sep 8;12(9):e0184508.
  2. Shigemizu D, Iwase T, Yoshimoto M, Suzuki Y, Miya F, Boroevich KA, Katagiri T, Zembutsu H*, Tsunoda T*. The prediction models for postoperative overall survival and disease-free survival in patients with breast cancer. Cancer Med. 2017 Jul;6(7):1627-1638
  3. 〇Yoshimaru T, Ono M, Bando Y, Chen YA, Mizuguchi K, Shima H, Komatsu M, Imoto I, Izumi K, Honda J, Miyoshi Y, Sasa M, Katagiri T*. A-kinase anchoring protein BIG3 coordinates oestrogen signaling in breast cancer cells. Nat Commun. 2017 May 30;8:15427. 【報道発表】乳がん細胞における新規エストロゲンシグナル制御機構の解明 〜新しいがん抑制因子の不活化機構の発見〜
  4. 〇Yoshimaru T*, Aihara K, Komatsu M, Matsushita Y, Okazaki Y, Toyokuni S, Honda J, Sasa M, Miyoshi Y, Otaka A, Katagiri T*. Stapled BIG3 helical peptide ERAP extends potent antitumor activity for breast cancer therapeutics. Sci Rep. 2017 May 12;7(1):1821 「報道発表」分子内架橋型ペプチドによるホルモン依存性乳がんの新規治療法の開発 〜臨床応用を見据えたペプチドの改良〜
  5. Iwamoto T*, Katagiri T, Niikura N, Miyoshi Y, Kochi M, Nogami T, Shien T, Motoki T, Taira N, Omori M, Tokuda Y, Fujiwara T, Doihara H, Gyorffy B, Matsuoka J. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers. Oncotarget. 2017 Apr 18;8(16):26122-26128.
  6. Shikata Y, Yoshimaru T, Komatsu M, Katoh H, Sato R, Kanagaki S, Okazaki Y, Toyokuni S, Tashiro E, Ishikawa S, Katagiri T, Imoto M*. Protein kinase A inhibition facilitates the antitumor activity of xanthohumol, a valosin-containing protein inhibitor. Cancer Sci. 2017 Apr;108(4):785-794.
  7. ○Uno Y*, Takata R, Kito G, Yamazaki Y, Nakagawa K , Nakamura Y, Kamataki T, Katagiri T*. Sex- and age-dependent gene expression in human liver: an implication for drug-metabolizing enzymes. Drug Metabolism and Pharmacokinetics. 2017 Feb;32(1):100-107.
  8. Obara W*, Karashima T, Takeda K, Kato R, Kato Y, Kanehira M, Takata R, Inoue K, Katagiri T, Shuin T, Nakamura Y, Fujioka T. Effective induction of cytotoxic T cells recognizing an epitope peptide derived from Hypoxia-Inducible Protein 2 (HIG2) in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother. 2017 Jan;66(1):17-24..


2016

  1. ○Nakamura T, Katagiri T, Sato S, Kushibiki T, Tsuchikawa T, Hirano S, Nakamura Y. Overexpression of C16orf74 is involved in aggressive pancreatic cancers. Oncotarget. 2016 Jul 28. doi: 10.18632/oncotarget.10912.
  2. Park JH, Jang M, Tarhan YM, Katagiri T, Sasa M, Miyoshi Y, Kalari KR, Suman VJ, Weinshilboum R, Wang L, Boughey JC, Goetz MP, Nakamura Y. Clonal expansion of anti-tumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy. Int J Oncol. 2016 Aug;49(2):471-8.


2015

  1. Imamura M, Nishimukai A, Higuchi T, Ozawa H, Yanai A, Miyagawa Y, Murase K, Sakita I, Hatada T, Takatsuka Y, Katagiri T, Miyoshi Y. High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patients. Breast Cancer Res Treat. 2015 Dec;154(3):521-31.
  2. Kim NH,Yoshimaru T, Chen Y, Matsuo T, Komatsu M, Miyoshi Y, Tanaka E, Sasa M, Mizuguchi K, Katagiri T*. BIG3 inhibits the estrogen-dependent nuclear translocation of PHB2 via multiple Karyopherin-alpha proteins in breast cancer cells. PLoS One. 2015 Jun 8;10(6):e0127707.
  3. Yoshimaru T,Komatsu M, Miyoshi, Honda J, Sasa M, Katagiri T*. Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. Cancer Sci. 2015 May;106(5):550-8.
  4. Yanai A, Inoue N, Yagi T, Nishimukai A, Miyagawa Y, Murase K, Imamura M, Enomoto Y, Takatsuka Y, Watanabe T, Hirota S, Sasa M, Katagiri T, Miyoshi Y. Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER+, and HER2- Breast Cancer. Clin Breast Cancer. 2015 Jun;15(3):197-203.
  5. Lo PH, Tanikawa C, Katagiri T, Nakamura Y, Matsuda K. Identification of novel epigenetically inactivated gene, PAMR1 in breast carcinoma. Oncol Rep. 2015 Jan;33(1):267-73.


2014

  1. Yoshimaru T, Komatsu M, Tashiro E, Imoto M, Osada H, Miyoshi Y, Honda J, Sasa M, Katagiri T*. Xanthohumol suppresses oestrogen-signalling in breast cancer through the specific inhibition of BIG3-PHB2 interactions. Sci Rep. 2014. Dec 8;4:7355.
  2. Matsuo T, Dat LT, Komatsu M, Yoshimaru T, Daizumoto K, Sone S, Nishioka Y, Katagiri T*. Early growth response 4 is involved in cell proliferation of small cell lung cancer through transcriptional activation of its downstream genes. PLoS One. 2014 Nov 20;9(11):e113606. PubMed
  3. ○Chen YA, Murakami Y, Ahmad S, Yoshimaru T, Katagri T, Mizuguchi K. Brefeldin a-inhibited guanine nucleotide-exchange protein 3 (BIG3) is predicted to interact with its partner through an ARM-type alpha-helical structure. BMC Res Notes. 2014 Jul 6;7(1):435.
  4. Yoshimura S, Tsunoda T, Osawa R, Harada M, Watanabe T, Hikichi T, Katsuda M, Miyazawa M, Tani M, Iwahashi M, Takeda K, Katagiri T, Nakamura Y, Yamaue H. Identification of an HLA-A2-restricted epitope peptide derived from hypoxia-inducible protein 2 (HIG2). PLoS One 2014 Jan 8;9(1):e85267.
  5. Matsuo T, Komatsu M, Yoshimaru T, Kiyotani K, Miyoshi Y, Sasa M, Katagiri T*. Involvement of B3GALNT2 overexpression in cell growth of breast cancer. Int J Oncol. 2014 Feb;44(2):427-34.


2013

  1. ○Low SK, Takahashi A, Ashikawa K, Inazawa J, Miki Y, Kubo M, Nakamura Y, Katagiri T. Genome-wide association study of breast cancer in the Japanese population. PLoS One. 2013 Oct 15;8(10):e76463.
  2. Yoshimaru T,Komatsu M, Matsuo T, Chen YA, Murakami,Y Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Yamaguchi R, Imoto S, Miyano S, Miyoshi Y, Sasa M, Nakamura Y, Katagiri T*. Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat. Communi. 2013;4:e2443.
  3. Yanai A, Miyagawa Y, Murase K, Imamura M, Yagi T, Ichii S, Takatsuka Y, Ito T, Hirota S, Sasa M, Katagiri T, Miyoshi Y. Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancers. Int J Clin Oncol. 2013 Jul 3.
  4. Kajita Y, Kato T Jr, Tamaki S, Furu M, Takahashi R, Nagayama S, Aoyama T, Nishiyama H, Nakamura E, Katagiri T, Nakamura Y, Ogawa O, Toguchida J. The transcription factor Sp3 regulates the expression of a metastasis-related marker of sarcoma, actin filament-associated protein 1-like 1 (AFAP1L1). PLoS One. 2013;8(1): e49709
  5. Komatsu M, Yoshimaru T, Matsuo T, Kiyotani, K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Miyano S, Nakamura Y, Sasa M, Shimada M, Katagiri T*. Molecular features of triple negative breast cancers by genome-wide gene expression profiling analysis. Int J Oncol. 2013 Feb;42(2):478-506


2012

  1. Fukawa T, Ono M, Matsuo T, Uehara H, Miki T, Nakamura Y, Kanayama H, Katagiri T*. DDX31 regulates the p53-HDM2 pathway and rRNA gene transcription through its interaction with NPM1 in renal cell carcinomas. Cancer Res. 2012 Nov 15;72(22):5867-77 [PubMed]
  2. Obara W, Ohsawa R, Kanehira M, Takata R, Tsunoda T, Yoshida K, Takeda K, Katagiri T, Nakamura Y, Fujioka T. Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer. Jpn J Clin Oncol. 2012 Jul;42(7):591-600.
  3. Murase K, Yanai A, Saito M, Imamura M, Miyagawa Y, Takatsuka Y, Inoue N, Ito T, Hirota S, Sasa M, Katagiri T, Fujimoto Y, Hatada T, Ichii S, Nishizaki T, Tomita N, Miyoshi Y. Biological characteristics of luminal subtypes in pre- and postmenopausal estrogen receptor-positive and HER2-negative breast cancers. Breast Cancer. 2012 Feb 23 (Epub) 2014.Jan21(1):52-7.
  4. Yoshioka H, Yamamoto S, Hanaoka H, Iida Y, Pramila P, Bishnuhari P, Higuchi T, Tominaga H, Oriuchi N, Nakagawa H, Shiba Y, Yoshida K, Osawa R, Katagiri T, Tsunoda T, Nakamura Y, Endo K. In vivo therapeutic effect of CDH3/P-Cadherin-targeting radioimmunotherapy. Cancer Immunol. Immunother. 2012; 61:1211-20.
  5. ○Dat LT, Matsuo T, Yoshimaru T, Kakiuchi S, Goto H, Hanibuchi M, Kuramoto T, Nishioka Y, Sone S, Katagiri T*. Identification of genes potentially involved in bone-metastasis by genome-wide gene-expression profiling analysis of non-small cell lung cancer in mice. Int J Oncol. 2012; 40:1455-69.[PubMed]


2011

  1. Kawai T, Caaveiro JM, Abe R, Katagiri T, Tsumoto K. Catalytic activity of MsbA reconstituted in nanodisc particles is modulated by remote interactions with the bilayer. FEBS Lett. 2011;585:3533-7. [PubMed]
  2. Furu M, Kajita Y, Nagayama S, Ishibe T, Shima Y, Uejima D, Aoyama T, Nakayama T, Nakamura T, Nakashima Y, Ikegawa M, Imoto S, Katagiri T, Nakamura Y, Toguchida J. Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas. Oncogene. 2011; 30: 4015-25. [PubMed]
  3. ○Park J, Katagiri T, Chung S, Kijima K, Nakamura Y. Polypeptide N-acetylgalactosaminyltransferase 6 (GALNT6) disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 2011;13:320-6. [PubMed]


2010

  1. ○Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y, Katagiri T. Critical roles of MUC1 glycosylation by transactivated GALNT6 (UDP-N-acetyl-D- galactosamine: polypeptide N-acetylgalactosaminyl transferase-6) in mammary carcinogenesis. Cancer Res. 2010;70:2759-69.
  2. ○Park JH, Nishidate T, Nakamura Y, Katagiri T. Critical roles of T-LAK cell-originated protein kinase in cytokinesis. Cancer Sci. 2010;101:403-11.


2009

  1. ○Ueki T, Park JH, Nishidate T, Kijima K, Hirata H, Nakamura Y, Katagiri T. Ubiquitination and downregulation of BRCA1 by UBE2T overexpression in human breast cancer cells. Cancer Res. 2009;69:8752-60.
  2. Ajiro M, Katagiri T, Ueda K, Nakagawa H, Fukukawa C, Lin ML, Park JH, Nishidate T, Daigo Y, Nakamura Y. Involvement of RQCD1 overexpression, a novel cancer-testis antigen, in the Akt pathway in breast cancer cells. Int J Oncol. 2009; 35:673-81.
  3. ○Kim JW, Akiyama M, Park JH, Lin ML, Shimo A, Ueki T, Daigo Y, Tatsuhiko T, Nishidate T, Nakamura Y, Katagiri T. Activation of an estrogen/ estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 2009;100:1468-78.
  4. ○Lin ML, Fukukawa C, Park JH, Naito K, Kijima K, Shimo A, Ajiro M, Nishidate T, Nakamura Y, Katagiri T. Involvement of overexpression of G-patch domain containing 2 in breast carcinogenesis. Cancer Sci. 2009;100:1443-50.
  5. Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci. 2009;100:1227-33.
  6. Hanaoka H, Katagiri T, Fukukawa C, Yoshioka H, Yamamoto S, Iida Y, Higuchi T, Oriuchi N, Paudyal B, Paudyal P, Nakamura Y, Endo K. Radioimmunotherapy of solid tumors targeting a cell-surface protein, FZD10. Annuals of Nuclear Medicine, 2009;23:479-85.
  7. Ueda K, Fukase Y, Katagiri T, Ishikawa N, Irie S, Sato T, Ito H, Nakayama H, Miyagi Y, Tsuchiya E, Kohno N, Shiwa M, Nakamura Y, Daigo Y. Targeted serum glycoproteomics for the discovery of lung cancer-associated glycosylation disorders using lectin-coupled ProteinChip arrays. Proteomics 2009; 9:2182-92.
  8. ○Dobashi S, Katagiri T, Hirota E, Ashida S, Daigo Y, Shuin T, Fujioka T, Miki T, Nakamura Y. Involvement of TMEM22 overexpression in the growth of renal cell carcinoma cells. Oncol Rep. 2009;21:305-12.
  9. ○Fukukawa C, Nagayama S, Tsunoda T, Toguchida J, Nakamura Y, Katagiri T. Activation of non-canonical Dvl-Rac1-JNK pathway by Frizzled-homologue 10 (FZD10) in human synovial sarcoma. Oncogene. 2009; 28:1110-20.
  10. Nagayama S, Yamada E, Kohno Y Aoyama T., Fukukawa C, Kubo H, Watanabe G, Katagiri T, Nakamura, Y, Sakai Y, Toguchida J. Inverse correlation of the upregulation of FZD10 expression and the activation of beta-catenin in synchronous colorectal tumors. Cancer Sci. 2009;99: 2315-26.


2008

  1. Inoue H, Iga M, Nabeta H, Yokoo T, Suehiro Y, Okano S, Inoue M, Kinoh H, Katagiri T, Takayama K, Yonemitsu Y, Hasegawa M, Nakamura Y, Nakanishi Y, Tani K. Non-transmissible SeV encoding GM-CSF is a novel and potent vector system to produce autologous tumor vaccines. Cancer Sci. 2008;99:2315-26.
  2. Konda R, Sugimura J, Sohma F, Katagiri T, Nakamura Y, Fujioka T. Over Expression of Hypoxia-Inducible Protein 2, Hypoxia-Inducible Factor-1 alpha and Nuclear Factor kappaB is putatively involved in acquired renal cyst formation and subsequent tumor transformation in patients with end stage renal failure. J Urol. 2008;180:481-5.
  3. ○Ueki T, Nihidate T, Park JH, Lin ML, Shimo A, Hirata K, Nakamura Y, Katagiri T. Involvement of elevated expression of multiple cell-cycle regulator, DTL/RAMP (denticleless /RA-regulated nuclear matrix associated protein), in the growth of breast cancer cells. Oncogene. 2008, in press.
  4. ○Fukukawa C, Hanaoka H, Nagayama S, Toguchida J, Endo K, Nakamura Y, Katagiri T. Radioimmunotherapy of human synovial sarcoma using a monoclonal antibody against FZD10. Cancer Sci. 2008; 99:432-40
  5. Kamatani Y, Matsuda K, Ohishi T, Ohtsubo S, Yamazaki K, Iida A, Hosono N, Kubo M, Yumura W, Nitta K, Katagiri T, Kawaguchi Y, Kamatani N, Nakamura Y. Identification of a significant association of a single nucleotide polymorphism in TNXB with systemic lupus erythematosus in a Japanese population. J Hum Genet. 2008;53:64-73.
  6. ○Shimo A, Tanikawa C, Lin ML, Nishidate T, Matsuda K, Ueki T, Park JH, Ohta T, Hirata K, Fukuda M, Nakamura Y, Katagiri T. Involvement of KIF2C/MCAK overexpression in mammary carcinogenesis. Cancer Sci. 2008;99:62-70.
  7. Kidokoro T, Tanikawa C, Furukawa Y, Katagiri T, Furukawa Y, Nakamura Y, Matsuda K. CDC20, a potential cancer therapeutic target, is negatively regulated by p53. Oncogene. 2008;27:1562-71.

原著論文(2007年以前)


2007

  1. Zembutsu H, Yanada M, Hishida A, Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T, Nakamura Y, Ohno R. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol. 2007;31:313-22.
  2. Senju S, Suemori H, Zembutsu H, Uemura Y, Hirata S, Fukuma D, Matsuyoshi H, Shimomura M, Haruta M, Fukushima S, Matsunaga Y, Katagiri T, Nakamura Y, Furuya M, Nakatsuji N, Nishimura Y. Genetically manipulated human embryonic stem cell-derived dendritic cells with immune regulatory function. Stem Cells. 2007;25:2720-9.
  3. Ueda K, Katagiri T, Shimada T, Irie S, Sato TA, Nakamura Y, Daigo Y. Comparative profiling of serum glycoproteome by sequential purification of glycoproteins and 2-nitrobenzensulfenyl (NBS) stable isotope labeling: a new approach for the novel biomarker discovery for cancer. J Proteome Res. 2007;6:3475-83.
  4. Fujikawa M, Katagiri T, Tugores A, Nakamura Y, Ishikawa F. ESE-3, an Ets family transcription factor, is up-regulated in cellular senescence. Cancer Sci. 2007;98:1468-75.
  5. Zembutsu H, Yanada M, Hishida A, Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T, Nakamura Y, Ohno R. Prediction of risk of disease recurrence by genome-wide cDNA microarray analysis in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with imatinib-combined chemotherapy. Int J Oncol. 2007;31:313-22.
  6. ○Kanehira M, Harada Y, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y, Katagiri T. Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis. Oncogene. 2007;26:6448-55.
  7. ○Kanehira M, Katagiri T, Shimo A, Takata R, Shuin T, Miki T, Fujioka T, Nakamura Y. Oncogenic role of MPHOSPH1, a cancer-testis antigen specific to human bladder cancer. Cancer Res. 2007;67:3276-85.
  8. ○Lin ML, Park JH, Nishidate T, Nakamura Y, Katagiri T. MELK, maternal embryonic leucine zipper kinase, involved in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of Bcl-2 family. Breast Cancer Res. 2007;9:R17, 1-13.
  9. ○Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y, Katagiri T. Elevated expression of PRC1, protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci. 2007;98:174-81.


2006

  1. ○Takata R, Katagiri T, Kanehira M, Shuin T, Miki T, Namiki M, Kohri K, Tsunoda T, Fujioka T, Nakamura Y. Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy. Cancer Sci. 2006;98:113-7.
  2. ○Park JH, Lin ML, Nishidate T, Nakamura Y, Katagiri T. PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen having an oncogenic activity in breast cancer. Cancer Res. 2006;66:9186-95.
  3. Iiizumi M, Hosokawa M, Takehara A, Chung S, Nakamura T, Katagiri T, Eguchi H, Ohigashi H, Ishikawa O, Nakamura Y, Nakagawa H. EphA4 receptor, overexpressed in pancreatic ductal adenocarcinoma, promotes cancer cell growth. Cancer Sci. 2006;97:1211-6.
  4. Takehara A, Eguchi H, Ohigashi H, Ishikawa O, Kasugai T, Hosokawa M, Katagiri T, Nakamura Y, Nakagawa H. Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4. Cancer Sci. 2006;97:1191-7.
  5. ○Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, Miki T, Nakamura Y, Katagiri T. Genome-wide gene expression profiles of clear cell renal cell carcinoma; Identification of molecular targets for treatment of renal cell carcinoma. Int J Oncol. 2006;29:799-827.
  6. Ashida S, Furihata M, Katagiri T, Tamura K, Anazawa Y, Yoshioka M, Miki T, Fujioka T, Shuin T, Nakamura Y, Nakagawa H. Expression of novel molecules, MICAL2-PV (MICAL2 prostate cancer variants), increases with high Gleason score and prostate cancer progression. Clin Cancer Res. 2006;12:2767-73.
  7. Hamamoto R, Silva FP, Tsuge M, Nishidate T, Katagiri T, Nakamura, Furukawa Y. Enhanced SMYD3 expression is essential for the growth of breast cancer cells. Cancer Sci. 2006;97:113-8.
  8. Kikuchi T, Daigo Y, Ishikawa N, Katagiri T, Tsunoda T, Yoshida S, Nakamura Y. Expression profiles of metastatic brain tumor from lung adenocarcinomas on cDNA microarray. Int J Oncol. 2006;4:799-805.
  9. Morris JR, Pangon L, Boutell C, Katagiri T, Keep NH, Solomon E. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. Hum Mol Genet. 2006;15:599-606.
  10. ○Tachiiri S, Katagiri T, Tsunoda T, Oya N, Hiraoka M, Nakamura Y. Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts. Int J Radiat Oncol Biol Phys. 2006;64:272-9.


2005

  1. Anazawa Y, Nakagawa H, Furihara M, Ashida S, Tamura K, Yoshioka H, Shuin T, Fujioka, Katagiri T, Nakamura Y. Analysis of gene-expression profiles after gamma irradiation of normal human fibroblasts. PCOTH, a novel gene overexpressed in prostate cancers, promotes prostate cancer cell growth through phosphorylation of oncoprotein TAF-Ibeta/SET. Cancer Res. 2005;65:4578-86.
  2. Obama K, Ura K, Li M, Katagiri T, Tsunoda T, Nomura A, Satoh S, Nakamura Y, Furukawa Y. Genome-wide analysis of gene expression in human intrahepatic cholangiocarcinoma. Hepatology. 2005;41:1339-48.
  3. ○Nagayama S, Fukukawa C, Katagiri T, Okamoto T, Aoyama T, Oyaizu N, Imamura M, Toguchida J, Nakamura Y. Therapeutic potential of antibodies against FZD10, a cell-surface protein, for synovial sarcomas. Oncogene. 2005;24:6201-12.
  4. ○Togashi A, Katagiri T, Ashida S, Fujioka T, Maruyama O, Wakumoto Y, Sakamoto Y, Fujime M, Kawachi Y, Shuin T, Nakamura Y. Hypoxia-inducible protein 2 (HIG2), a novel diagnostic marker for renal cell carcinoma (RCC) and potential target for molecular therapy. Cancer Res. 2005;65:4817-26.
  5. ○Takata R, Katagiri T, Kanehira M, Tsunoda T, Shuin T, Miki T, Namiki M, Kohri K, Matsushita Y, Fujioka T, Nakamura Y. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin Cancer Res. 2005;11:2625-36.
  6. Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y, Nakamura T, Toguchida J. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res. 2005;11:2702-12.
  7. Taniuchi K, Nakagawa H, Hosokawa M, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. Overexpressed P-cadherin/CDH3 promotes motility of pancreatic cancer cells by interacting with p120ctn and activating rho-family GTPases. Cancer Res. 2005;65:3092-9.
  8. Taniuchi K, Nakagawa H, Nakamura T, Eguchi H, Ohigashi H, Ishikawa O, Katagiri T, Nakamura Y. Down-regulation of RAB6KIFL/KIF20A, a kinesin involved with membrane trafficking of discs large homologue 5, can attenuate growth of pancreatic cancer cell. Cancer Res. 2005;65:105-12.


2004

  1. Nakatsura T, Komori H, Kubo, Y. Yoshitake, S. Senju, Katagiri T, Furukawa Y, Ogawa M, Nakamura Y, Nishimura Y. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice. Clin Cancer Res. 2004;10:8630-40.
  2. ○Kamiyama H, Kurosaki K, Kurimoto M, Katagiri T, Nakamura Y, Kurokawa M, Sato H, Endo S, Shiraki K. Herpes simplex virus-induced, death receptor-dependent apoptosis and regression of transplanted human cancers. Cancer Sci. 2004;95:990-8.
  3. ○Okada K, Hirota E, Mizutani Y, Fujioka T, Shuin T, Miki T, Nakamura Y, Katagiri T. Oncogenic role of NALP7 in testicular seminomas. Cancer Sci. 2004;95:949-54.
  4. Yoshitake Y, Nakatsura T, Monji M, Senju S, Matsuyoshi H, Tsukamoto H, Hosaka S, Komori H, Fukuma D, Ikuta Y, Katagiri T, Furukawa Y, Ito H, Shinohara M, Nakamura Y, Nishimura Y. Proliferation potential-related protein, an ideal esophageal cancer antigen for immunotherapy, identified using complementary DNA microarray analysis. Clin Cancer Res. 2004;10:6437-48.
  5. ○Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K, Nakamura Y. Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol. 2004;25:797-819.
  6. Ashida S, Nakagawa H, Katagiri T, M. Furihata, M. Iiizumi, Y. Anazawa, Tsunoda T, R. Takata, K. Kasahara, T. Miki, T. Fujioka, T. Shuin, Nakamura Y. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: genome-wide gene-expression profiles of prostate cancers and PINs. Cancer Res. 2004;64:5963-72.
  7. ○Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, Nakamura Y, Katagiri T. Prediction of outcome of advanced cervical cancer to thermoradiotherapy according to expression profiles of 35 genes selected by cDNA microarray analysis. Int J Radiat Oncol Biol Phys. 2004;60:237-48.
  8. ○Nagayama S, Iiizumi M, Katagiri T, Toguchida J, Nakamura Y. Identification of PDZK4, a novel human gene with PDZ domains, that is up-regulated in synovial sarcomas. Oncogene. 2004;23:5551-7.
  9. Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H, Nakamura Y. Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Oncol. 2004;24:647-55.
  10. ○Nakamura T, Furukawa Y, Nakagawa H, Tsunoda T, Ohigashi H, Murata K, Ishikawa O, Ohgaki K, Kashimura N, Miyamoto M, Hirano S, Kondo S, Katoh H, Nakamura Y, Katagiri T. Genome-wide cDNA microarray analysis of gene-expression profiles in pancreatic cancers using populations of tumor cells and normal ductal epithelial cells selected for purity by laser microdissection. Oncogene. 2004;23:2385-400.
  11. Li M, Lin YM, Hasegawa S, Shimokawa T, Murata K, Kameyama M, Ishikawa O, Katagiri T, Tsunoda T, Nakamura Y, Furukawa Y. Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol. 2004;24:305-12.


2003

  1. ○Okada K, Katagiri T, Tsunoda T, Mizutani Y, Suzuki Y, Kamada M, Fujioka T, Shuin T, Miki T, Nakamura Y. Analysis of gene-expression profiles in testicular seminomas using a genome-wide cDNA microarray. Int J Oncol. 2003;23:1615-35.
  2. Suzuki C, Daigo Y, Kikuchi T, Katagiri T, Nakamura Y. Identification of COX17 as a therapeutic target for non-small cell lung cancer. Cancer Res. 2003;63:7038-41.
  3. ○Kaneta Y, Kagami Y, Tsunoda T, Ohno R, Nakamura Y, Katagiri T. Genome-wide analysis of gene-expression profiles in chronic myeloid leukemia cells using a cDNA microarray. Int J Oncol. 2003;23:681-91.
  4. Zembutsu H, Ohnishi Y, Daigo Y, Katagiri T, Kikuchi T, Kakiuchi S, Nishime C, Hirata K, Nakamura Y. Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839. Int J Oncol. 2003;23:29-39.
  5. Nakatsura T, Yoshitake Y, Senju S, Monji M, Komori H, Motomura Y, Hosaka S, Beppu T, Ishiko T, Kamohara H, Ashihara H, Katagiri T, Furukawa Y, Fujiyama S, Ogawa M, Nakamura Y, Nishimura Y. Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker. Biochem Biophys Res Commun. 2003;306:16-25.
  6. Ochi K, Daigo Y, Katagiri T, Saito-Hisaminato A, Tsunoda T, Toyama Y, Matsumoto H, Nakamura Y. Expression profiles of two types of human knee-joint cartilage. J Hum Genet. 2003;48:177-82.
  7. Kikuchi T, Daigo Y, Katagiri T, Tsunoda T, Okada K, Kakiuchi S, Zembutsu H, Furukawa Y, Kawamura M, Kobayashi K, Imai K, Nakamura Y. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;22:2192-205.
  8. ○Arimoto T, Katagiri T, Oda K, Tsunoda T, Yasugi T, Osuga Y, Yoshikawa H, Nishii O, Yano T, Taketani Y, Nakamura Y. Genome-wide cDNA microarray analysis of gene-expression profiles involved in ovarian endometriosis. Int J Oncol. 22:551-60.
  9. Abe S, Katagiri T, Saito-Hisaminato A, Usami S, Inoue Y, Tsunoda T, Nakamura Y. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues. Identification of CRYM as a candidate responsible for nonsyndromic deafness, through cDNA microarray analysis of human cochlear and vestibular tissues. Am J Hum Genet. 2003;72:73-82.


2002

  1. ○Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H, Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K, Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A, Wang Y, Motoji T, Ohno R, Nakamura Y. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther. 2002;1:1035-42.
  2. Hasegawa S, Furukawa Y, Li M, Satoh S, Kato T, Watanabe T, Katagiri T, Tsunoda T, Yamaoka Y, Nakamura Y. Genome-wide analysis of gene expression in intestinal-type gastric cancers using a complementary DNA microarray representing 23,040 genes. Cancer Res. 2002;62:7012-7.
  3. ○Nagamaya S, Katagiri T, Tsunoda T, Hosaka T, Nakashima Y, Araki N, Kusuzaki K, Nakayama T, Tsuboyama T, Nakamura T, Imamura M, Nakamura Y, Toguchida J. Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res. 62:5859-66.
  4. Brown M, Nicolai H, Howe K, Katagiri T, Lalani E, Simpson K, Manning N, Deans A, Chen P, Khanna KK, Wati MR, Griffiths B, Xu C, Stamp G, Solomon E. Expression of a truncated Brca1 protein delays lactational mammary development in transgenic mice. Transgenic Res. 2002;11:467-78.
  5. ○Kaneta Y, Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, Hirai H, Ohnishi K, Ueda T, Emi N, Tomida A, Tsuruo T, Nakamura Y, Ohno R. Prediction of sensitivity to STI571 among chronic myeroid leukemia patients by genome-wide cDNA microarray analysis. Jpn J Cancer Res. 2002;93:849-56.
  6. ○Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y. Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia. 2002;4:295-303.
  7. ○Saito-Hisaminato A*, Katagiri T*, Kakiuchi S, Nakamura T, Tsunoda T, Nakamura Y. Genome-wide profiling of gene expression in 29 normal human tissues with a cDNA microarray. DNA Res. 2002;9:35-45. (*equal contributors)
  8. Miura K, Bowman ED, Simon R, Peng AC, Robles AI, Jones RT, Katagiri T, He P, Mizukami H, Charboneau L, Kikuchi T, Liotta LA, Nakamura Y, Harris CC. Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking and prognosis-related molecular profiles. Cancer Res. 2002;62:3244-50.
  9. Dan S, Tsunoda T, Kitahara O, Yanagawa R, Zembutsu H, Katagiri T, Yamazaki K, Nakamura Y, Yamori T. An integrated database of chemosensitivity to 55 anticancer drugs. Cancer Res. 2002;62:1139-47.
  10. Zembutsu H, Ohnishi Y, Tsunoda T, Furukawa Y, Katagiri T, Ueyama Y, Tamaoki N, Nomura T, Kitahara O, Yanagawa R, Hirata K, Nakamura Y. Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. Cancer Res. 2002;62:518-27.


2001

  1. Maeda K, Matsuhashi S, Tabuchi K, Watanabe T, Katagiri T, Oyasu M, Saito N, Kuroda S. Brain specific human genes, NELL1 and NELL2, are predominantly expressed in neuroblastoma and other embryonal neuroepithelial tumors. Neurol Med Chir. 2001;41:582-8.

2000

  1. Kato M, Yano K, Matsuo F, Saito H, Katagiri T, Kurumizaka H, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Nagawa H, Nakamura Y, Miki Y. Identification of Rad51 alteration in patients with bilateral breast cancer. J Human Genet. 2000;45:133-7.
  2. Futamura M, Arakawa H, Matsuda K, Katagiri T, Saji S, Miki Y, Nakamura Y. Potential role of BRCA2 in a mitotic checkpoint after phosphorylation by hBUBR1. Cancer Res. 2000;60:1531-5.


1999

  1. Emi M, Yoshimoto M, Sato T, Matsumoto S, Y. Utada, I. Ito, K. Minobe, T. Iwase, Katagiri T, Bando K, Akiyama F, Harada Y, Fukino K, Sakamoto G, Matsushima M, Iida A, Tada T, Saito H, Miki Y, Kasumi F, Nakamura Y. Allelic loss at 1p34, 13q12, 17p13.3, and 17q21.1 correlates with poor postoperative prognosis in breast cancer. Genes Chromosomes Cancer. 1999;26:134-41.
  2. Katagiri T, Futamura M, Nakamura Y. A Gln/Arg polymorphism at codon 349 of the hBUBR1 gene. J Human Genet. 1999;44:131-2.


1998

  1. Maruyama O, Nishimori H, Katagiri T, Miki Y, Ueno A, Nakamura Y. Cloning of TCFL5 encoding a novel human basic helix-loop-helix motif protein that is specifically expressed in primary spermatocytes at the pachytene stage. Cytogenet Cell Genet. 1998;82:41-5.
  2. Katagiri T, Saito H, Shinohara A, Ogawa H, Kamada N, Nakamura Y, Miki Y. Multiple possible sites of BRCA2 interacting with DNA repair protein Rad51. Genes Chromosomes Cancer. 1998;21:217-22.
  3. Katagiri T, Kasumi F, Yoshimoto M, Asaishi K, Abe R, Tsuchiya A, Sugano M, Nomizu T, Takai S, Yoneda M, Nanba K, Makita M, Okazaki H, Hirata K, Okazaki M, Furutsuma Y, Morishita Y, Iino Y, Karino T, Fukutomi T, Ayabe H, Hara S, Kajiwara T, Houga S, Shimizu T, Toda M, Yamasaki Y, Uchida T, Kunitomo K, Sonoo H, Kurebayashi J, Shimotuma K, Nakamura Y, Miki Y. High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. J Human Genet. 1998;43:42-8.
  4. Emi M, Matsushima M, Katagiri T, Yokota T, Nakata T, Kasumi F, Miki Y, Skolnick MH, Nakamura Y. Multiplex mutation screening of the BRCA1 gene in 1000 Japanese breast cancers: 2-3% of Japanese breast cancer is attributable to BRCA1 mutations. Jpn J Cancer Res.1998;89:12-4.


1997

  1. ○Miki Y, Katagiri T, Nakamura Y. Infrequent mutation of the H-Cadherin gene on chromosome 16q24 in human breast cancers. Jpn J Cancer Res. 1997;88:701-4.
  2. Shimizu F, Katagiri T, Suzuki M, Watanabe TK, Okuno S, Kuga Y, Nagata M, Fujiwara T, Nakamura Y, Takahashi E. Cloning and chromosome assignment to 1q32 of a human cDNA (RAB7L1) encoding a small GTP-binding protein, a member of the RAS superfamily. Cytogenet Cell Genet. 1997;77:261-3.
  3. Takeda S, Fujiwara T, Shimizu F, Kawai A, Shinomiya K, Okuno S, Ozaki K, Katagiri T, Shimada Y, Nagata M, Watanabe T, Takaichi A, Kuga Y, Suzuki M, Hishigaki H, Takahashi E, Shin S, Nakamura Y, Hirai Y. Isolation and mapping of karyopherin alpha 3 (KPNA3), a human gene that is highly homologous to genes encoding Xenopus importin, yeast SRP1 and human RCH1. Cytogenet Cell Genet. 1997;76:87-93.


1996

  1. ○Watanabe TK*, Katagiri T*, Suzuki M, Shimizu F, Fujiwara T, Kanemoto N, Nakamura Y, Hirai Y, Maekawa H, Takahashi E. Cloning and characterization of two novel human cDNAs (NELL1 and NELL2) encoding proteins with six EGF-like repeats. Genomics. 1996;38:273-6. (*equal contributors)
  2. Katagiri T, Ozaki K, Fujiwara T, Shimizu F, Kawai A, Okuno S, Suzuki M, Nakamura Y, Takahashi E, Hirai Y. Cloning, expression, and chromosome mapping of adducin-(alpha) like 1 (ADDL1), a human cDNA highly homologous to human erythrocyte adducin. Cytogenet Cell Genet. 1996;74:90-5.
  3. Katagiri T, Nakamura Y, Miki Y. Mutations in the BRCA2 gene in hepatocellular carcinomas. Cancer Res. 1996;56:4575-7.
  4. ○Miki Y, Katagiri T, Kasumi F, Yoshimoto T, Nakamura Y. Mutation analysis in the BRCA2 gene in primary breast cancers. Nature Genet. 1996;13: 245-7.
  5. Katagiri T, Emi M, Ito I, Kobayashi K, Yoshimoto M, Watanabe S, Iwase T, Kasumi F, Miki Y, Skolnick MH, Nakamura Y. Mutations in the BRCA1 gene in Japanese breast cancer patients. Human Mutat. 1996;7:334-9.


1995

  1. Ito I, Yoshimoto M, Iwase T, Watanabe S, Katagiri T, Harada Y, Kasumi F, Yasuda S, Mitomi T, Emi M, Nakamura Y. Association of genetic alterations on chromosome 17 and loss of hormone receptors in breast cancer. Br J Cancer. 1995;71:438-41.
  2. Katagiri T, Harada Y, Emi M, Nakamura Y. Human metalloprotease/ disintegrin-like (MDC) gene: exon-intron organization and alternative splicing. Cytogenet Cell Genetics. 1995;68:39-44.


1994

  1. ○Harada Y, Katagiri T, Ito I, Akiyama F, Sakamoto G, Kasumi F, Nakamura Y, Emi M. Genetic studies of 457 breast cancers. Clinicopathologic parameters compared with genetic alterations. Cancer. 1994;74:2281-6.
  2. Isomura M, Tanigami A, Saito H, Harada Y, Katagiri T, Inazawa J, Ledbetter DH, Nakamura Y. Detailed analysis of heterozygosity on chromosome band 17p13 in breast carcinoma on the basis of a high-resolution physical map with 29 markers. Genes Chromosomes Cancer. 1994;9:173-9.


1993

  1. ○Emi M, Katagiri T, Harada Y, Saito H, Inazawa J, Ito I, Kasumi F, Nakamura Y. A novel metalloprotease/ disintegrin-like gene at 17q21.3 is somatically rearranged in two primary breast cancers. Nature Genet. 1993;5: 151-7.
  2. ○Ichii M, Katagiri T, Hasegawa H, Yatou O, Kirk DW, Wray JL. Biochemical characterization of rice (Oryza sativa L.) mutants defective or low in nitrate reduction. Tech Bull Fac Agric Kagawa University. 1995;47:1-6.
  3. ○Ichii M, Katagiri T, Hasegawa H. Mutants with low nitrate reductase activity selected from seedlings expressing nitrogen deficiency symptoms in rice (Oryza sativa L.). Jpn J Breed. 1993;43:123-7.


1992

  1. ○Hasegawa H, Katagiri T, Ida S, Yatou O, Ichii M. Characterization of a rice (Oryza sativa L.) mutant deficient in the heme domain of nitrate reductase. Theor Appl Genet. 1992;84:6-9.


1991

  1. ○Hasegawa H, Yatou O, Katagiri T, Ichii M. Screening for nitrate reductase deficient mutants in rice (Oryza sativa L.). Jpn J Breed. 1991;41:95-101.

欧文総説

  1. ○Fukukawa C, Nakamura Y, Katagiri T. Molecular target therapy for synovial sarcoma. Future Oncology. 2005;1:805-12.

和文

吉丸哲郎、片桐豊雅
乳がんにおける新規がん抑制因子不活化機構の解明と創薬研究 p74-79
Precision Medicine Vo.1, No.1「プレシジョンメディシンと創薬 (Precision Medicine & Drug Development), 2018

片桐豊雅
浸潤性膀胱癌の分子機構 p208-213
日本臨牀75巻 増刊号8「がん転移学(上)」(2017年11月20日発行)

松下洋輔、吉丸哲郎、片桐豊雅
包括的ゲノム解析を通じた乳がんの発症・進展機構解明の現状と展望
日本臨牀75巻増刊号3「乳癌学−最新の診断と治療」(2017年4月20日発行)

吉丸哲郎、松下洋輔、片桐豊雅 :
包括的ゲノム解析を通じたトリプルネガティブ乳がんの分子特性
乳癌の臨床、Vol31, No.5, 377-385, 2016

片桐豊雅・吉丸哲郎 :
新規エストロゲンシグナル制御分子BIG3を標的とした乳がん治療薬の創製
細胞, Vol.46 (11) 524-528頁, 2014

片桐豊雅 :
ゲノム解析によるトリプルネガティブ乳癌の特性解明
Bressance, Vol.6, 134-138頁, 2013

片桐豊雅 :
腎細胞癌特異的分子を標的とした創薬研究
西日本泌尿器科, Vol.75, 2013

片桐豊雅 :
乳がんにおけるがん特異的Oー結合型糖転移酵素標的治療薬の開発
次世代がん戦略研究 Update がん基盤生物学(南山堂)、 300-303頁, 2013

片桐豊雅 :
Cancer diagnosis,
日本臨牀, Vol.68 Suppl 8, 134-138頁, 2010

片桐豊雅 :
ミトコンドリアが小胞体と並んでいるわけは?
実験医学, Vol.27, No.4, 528-529, 2009.

片桐豊雅・高田亮・藤岡知昭・中村祐輔
網羅的発現情報解析を利用した癌の新規治療薬開発への戦略
がん分子標的治療研究. 2009:279-285.

片桐豊雅・中村祐輔
腎細胞癌における新規診断および治療のための標的分子の同定
がん分子標的治療 (南山堂)  2008;67-72

中村祐輔(監修)牛島俊和・片桐豊雅・山田哲司・近藤科江(編集)
片桐豊雅 概論:ゲノム研究に基づく癌の個別化医療
実験医学増刊.2007;25:2608-14.

片桐豊雅・中村祐輔
腎細胞癌における新規診断および治療のための標的分子の同定
Cancer Frontier. 2007;9:127-36.

片桐豊雅・中村祐輔
網羅的発現情報解析を利用した癌の新規治療薬開発への戦略
バイオテクノロジージャーナル. 2007;7:296-300.

片桐豊雅・中村祐輔
遺伝子発現解析に基づいた抗がん剤感受性予測法の開発
放射線生物研究. 2006;41:245-54.

片桐豊雅・中村祐輔
慢性骨髄性白血病におけるグリベック感受性予測診断法の開発
臨床化学. 2005;34:102-7.

片桐豊雅・中村祐輔
グリベックに対する薬剤感受性診断
臨床検査. 2005;49:516-21.

片桐豊雅・中村祐輔
発現情報解析に基づく抗癌剤治療の最適化戦略
バイオベンチャー. 2003;3:13-21

片桐豊雅・三木義男
遺伝性癌 癌抑制遺伝子、癌遺伝子、DNA修復遺伝子の役割
実験医学. 1997;15:873-8.

片桐豊雅・三木義男
乳癌におけるBRCA1, BRCA2遺伝子の役割
Molecular Medicine.1997;34:706-12.

片桐豊雅・三木義男
家族性乳癌原因遺伝子探求の現状
実験医学. 1996;14:674-7.

片桐豊雅
疾患遺伝子解明と最前線、大動脈弁上部狭窄症
実験医学増刊.1994;12:218-9.

学会発表 (2009年以前)


主な学会発表(口演)

2009

  • Toyomasa Katagiri
  • Strategy for development of novel molecular-targeting drugs for breast cancer through gene-expression profile analysis (oral presentation)
  • Workshop Japan-Mexico "Genomic Medicine"
  • 日本ーメキシコ共同「ゲノム医学」ワークショップ東京大学医科学研究所, 2009.11.26
  • 片桐豊雅・中村祐輔
  • 遺伝子発現情報解析に基づいた乳癌新喫分子標的治療薬開発の戦略
  • 第68回日本癌学会学術総会 シンポジウム 分子情報を用いた個別化医療のTR
  • 横浜, 2009.10. 1-3
  • 松尾泰佑・中村 祐輔・片桐 豊雅
  • 遺伝子発現情報解析を通じた新規エストロゲン受容体活性化制御分子ERAP1の同定とその機能解析
  • 第13回日本がん分子標的治療学会学術集会、
  • 徳島, 2009. 6. 24-26
  • 片桐 豊雅・中村 祐輔
  • 分裂期キナーゼTOPKを標的とした新規治療薬開発の戦略
  • 第13回日本がん分子標的治療学会学術集会、シンポジウム1
  • 最先端創薬:ベンチサイドから前臨床までのステップアップ
  • 徳島, 2009. 6. 24-26



2008

  • Toyomasa Katagiri (International symposium, oral)
  • Identification of PBK/TOPK, Ser/Thr protein kinase as a druggable-target though analysis of genome-wide gene expression profile,
  • The 7th Sino-Japan Joint Conference for Cancer Research, Dec. 2008.
  • Toyomasa Katagiri, Yusuke Nakamura (International symposium, oral).
  • Identification of PBK/TOPK, Ser/Thr protein kinase, as a druggable-target for breast cancer therapy though analysis of genome-wide gene expression profile.,
  • Second JCA-AACR Special Joint Conference. The Latest Advances in Breast Cancer Research: From Basic Science to Therapeutics. Awaji-island, July 2008.
  • Toyomasa Katagiri, Yusuke Nakamura
  • 遺伝子発現情報解析による乳癌新規治療標的分子の同定とその機能解析,
  • 第67回日本癌学会学術総会 シンポジウム, Oct. 2008.
  • 片桐 豊雅・中村 祐輔
  • 遺伝子発現情報解析による乳癌新規治療標的分子の同定とその機能解析,
  • 第17回日本アポトーシス研究会・学術集会 シンポジウム, 2008年8月.
  • 片桐 豊雅・中村 祐輔
  • FZD10モノクローナル抗体を用いた滑膜肉腫に対する抗体療法の検討,
  • 第41回日本整形外科学会 骨・軟部腫瘍学術集会 シンポジウム, 2008年7月.


2007

  • Toyomasa Katagiri, Yusuke Nakamura (International symposium, oral)
  • Development of prediction system of response to M-VAC neoadjuvant chemotherapy for bladder cancer toward personalized medicine.
  • The 2007 EAUHGS symposium & the 7th EAUHGS Annual meeting, Changsha, Funan, China; Dec, 7-9, 2007.
  • 片桐豊雅・中村祐輔 
  • 遺伝子発現情報解析を利用した乳癌新規治療薬分子標的候補遺伝子の同定およびその機能解析(シンポジウム)
  • 第66回日本癌学会学術総会、横浜、2007年10月3-5日
  • 片桐豊雅・中村祐輔
  • オーダーメイド医療実現化に向けた抗がん剤効果予測法の開発(特別講演)
  • 第6回国際バイオEXPO&国際バイオフォーラムセミナー、東京、2007年6月20日
  • Toyomasa Katagiri, Yusuke Nakamura (International symposium, oral)
  • Development of prediction system of response to M-VAC neoadjuvant chemotherapy for bladder cancer.
  • 7th Joint conference of the American association for cancer research and the Japanese cancer association. Jan, 21-25, 2007


2006

  • 片桐豊雅
  • 滑膜肉腫分子標的治療を目的とした抗FZD10抗体の開発(シンポジウム)
  • 第3回日本癌学会カンファレンス(動物モデルによる新時代のがん研究−発症機構から治療まで)、蓼科、2006年3月11日
  • 片桐豊雅
  • 遺伝子発現解析に基づいた抗がん剤感受性予測(シンポジウム)
  • 第8回癌治療増感研究シンポジウム、奈良、2006年2月12日


2005

  • 片桐豊雅・中村祐輔
  • 遺伝子発現情報解析によるがんのオーダーメイド治療(シンポジウム)
  • 第64回日本癌学会学術総会、札幌、2005年9月14-16日
  • 片桐豊雅
  • 乳癌および卵巣癌とBRCA1(シンポジウム)
  • 第13回日本がん検診・診断学会、横浜、2005年7月1日
  • 片桐豊雅・中村祐輔
  • 泌尿器科癌における抗がん剤感受性予測システムの開発(シンポジウム)
  • 第93回日本泌尿器学会、東京、2005年4月16日
  • 片桐豊雅・中村祐輔
  • 遺伝子発現解析に基づいた抗がん剤感受性予測システムの開発
  • および分子標的薬候補遺伝子の解析(シンポジウム)
  • 第2回日本癌学会カンファレンス(がんゲノム研究の新戦略−オーダーメイド医療を目指して)、蓼科、2005年3月9-11日
  • 片桐豊雅・中村祐輔
  • 膀胱癌における遺伝子発現解析に基づいたMVAC療法感受性予測システムの開発および分子標的候補遺伝子の解析(特別講演)
  • 第14回泌尿器科分子細胞研究会、盛岡、2005年2月25日


2004

  • 片桐豊雅・中村祐輔
  • オーダーメイド医療実現に向けての抗がん剤感受性予測システムの開発(シンポジウム)
  • BioJapan 2004、東京、2004年9月28-30日
  • 片桐豊雅・中村祐輔
  • オーダーメイド医療実現に向けてのイマチニブ感受性予測システムの開発(シンポジウム)
  • 第51回臨床検査医学会総会・第44回臨床化学会年会連合大会、東京、2004年9月4日
  • 片桐豊雅・中村祐輔
  • オーダーメイド医療実現に向けての抗がん剤感受性予測システムの開発(シンポジウム)
  • ゲノム創薬フォーラム、東京、2004年7月14日
  • 片桐豊雅・中村祐輔
  • オーダーメイド医療実現に向けての抗がん剤感受性予測システムの開発(シンポジウム)
  • がん分子標的治療研究会、鹿児島、2004年5月13-14日


2003

  • 片桐豊雅・中村祐輔
  • 遺伝子発現解析に基づいた抗がん剤感受性予測(シンポジウム)
  • 第62回日本癌学会学術総会、名古屋、2003年9月25日


2002

  • Toyomasa Katagiri, Yusuke Nakamura (International symposium, oral)
  • Prediction of sensitivity to anticancer drugs in leukemia patients by genome-wide cDNA microarray analysis.
  • Molecular portraits of tumors, France, Nov 14-16, 2002.
  • Toyomasa Katagiri, Yusuke Nakamura (International symposium, oral)
  • Prediction of sensitivity to anticancer drugs in leukemia patients by genome-wide cDNA microarray analysis.
  • Italy-Japan Joint Meeting, Tokyo, Nov 4, 2002
  • 片桐豊雅・中村祐輔
  • 白血病細胞に対する遺伝子発現プロファイル解析(シンポジウム)
  • 第61回日本癌学会学術総会、名古屋、2002年9月25日